XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer

Study ID
NCT00215722

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination. This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.

More informations

Trial Starting Date

Jul 31,2005

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit